NCT03119558View on ClinicalTrials.gov

PET/MRI Evaluation of Cardiac Amyloid

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 26, 2016

Primary Completion Date

August 23, 2018

Study Completion Date

August 28, 2018

Conditions
Cardiac Amyloidosis
Interventions
DRUG

18F-Florbetaben (Neuraceq®) PET/MRI

Administration of 8.0 mCi 18F-Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT03119558 - PET/MRI Evaluation of Cardiac Amyloid | Biotech Hunter | Biotech Hunter